|Bid||0.8210 x 1100|
|Ask||0.8400 x 1200|
|Day's Range||0.8210 - 0.8400|
|52 Week Range||0.6900 - 2.6000|
|Beta (5Y Monthly)||1.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
PETACH TIKVA, Israel, November 25, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2022.
Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.
Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.